Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Sarcoma 2 Leukemia, Myeloid, Acute 2 Thymoma 1 Recurrence 1 Rectal Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, T-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Drug-Related Side Effects and Adverse Reactions 1

Interventions

130-nm albumin-bound paclitaxel 2 selinexor 1 pembrolizumab 1 isophosphamide mustard 1 epacadostat 1 Sunitinib 1 Ramucirumab 1 Radiotherapy 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Leucovorin 1 Histocompatibility Testing 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Epirubicin 1 Cyclophosphamide 1 Cisplatin 1 Chemoradiotherapy 1 Carboplatin 1 68Ga-pentixafor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Thymoma × selinexor × Clear all

NCT03466827 2018-03-15

TET-SEL

Rigshospitalet, Denmark

Phase 2 Unknown

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡